These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25800084)

  • 1. Transdermal contraception methods: today's patches and new options on the horizon.
    Nelson AL
    Expert Opin Pharmacother; 2015 Apr; 16(6):863-73. PubMed ID: 25800084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective multicentre study comparing levonorgestrel implants with a combined contraceptive pill: final results.
    Kirkman RJ; Bromham DR; O'Connor TP; Sahota JE
    Br J Fam Plann; 1999 Jul; 25(2):36-40. PubMed ID: 10454652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.
    Goa KL; Warner GT; Easthope SE
    Treat Endocrinol; 2003; 2(3):191-206. PubMed ID: 15966567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
    Merz M; Kroll R; Lynen R; Bangerter K
    Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra).
    Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit
    J Fam Plann Reprod Health Care; 2004 Jan; 30(1):43-5. PubMed ID: 15006313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study.
    Junge W; Heger-Mahn D; Trummer D; Merz M
    Drugs R D; 2013 Sep; 13(3):223-33. PubMed ID: 24043457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
    Henzl MR; Loomba PK
    J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer non-oral hormonal contraception.
    Bateson D; McNamee K; Briggs P
    BMJ; 2013 Feb; 346():f341. PubMed ID: 23412438
    [No Abstract]   [Full Text] [Related]  

  • 13. Transdermal hormonal contraception: benefits and risks.
    Burkman RT
    Am J Obstet Gynecol; 2007 Aug; 197(2):134.e1-6. PubMed ID: 17689623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.
    Wiegratz I; Bassol S; Weisberg E; Mellinger U; Merz M
    Reprod Sci; 2014 Dec; 21(12):1518-25. PubMed ID: 24784719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormonal contraceptive patch].
    Lidegaard O
    Ugeskr Laeger; 2004 Oct; 166(41):3591. PubMed ID: 15515462
    [No Abstract]   [Full Text] [Related]  

  • 16. Transdermal contraception.
    Creasy GW; Abrams LS; Fisher AC
    Semin Reprod Med; 2001 Dec; 19(4):373-80. PubMed ID: 11727179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system.
    Sriprasert I; Stanczyk FZ; Archer DF
    Expert Opin Pharmacother; 2015; 16(12):1901-9. PubMed ID: 26194214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transdermal contraceptive patch: a new approach to hormonal contraception.
    Burkman RT
    Int J Fertil Womens Med; 2002; 47(2):69-76. PubMed ID: 11991433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
    Radowicki S; Skórzewska K; Szlendak K
    Ginekol Pol; 2005 Nov; 76(11):884-9. PubMed ID: 16566363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical study of transdermal contraceptive patch in Thai adolescence women.
    Piyasirisilp R; Taneepanichskul S
    J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.